+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Dyslipidemia"

Peripheral Artery Disease Market - Global Strategic Business Report - Product Thumbnail Image

Peripheral Artery Disease Market - Global Strategic Business Report

  • Report
  • September 2026
  • 265 Pages
  • Global
From
Cardiovascular Care Market - Forecast from 2026 to 2031 - Product Thumbnail Image

Cardiovascular Care Market - Forecast from 2026 to 2031

  • Report
  • January 2026
  • 129 Pages
  • Global
From
American Heart Association (AHA): Scientific Sessions 2025 Highlights - Product Thumbnail Image

American Heart Association (AHA): Scientific Sessions 2025 Highlights

  • Report
  • November 2025
  • 20 Pages
  • United States
From
From
Loading Indicator

Dyslipidemia is a condition in which there is an abnormal amount of lipids (fats) in the blood. It is a major risk factor for cardiovascular disease, and is one of the most common conditions managed by cardiologists. Dyslipidemia is typically treated with lifestyle modifications, such as diet and exercise, as well as medications. Statins are the most commonly prescribed medications for dyslipidemia, and are used to reduce the levels of low-density lipoprotein (LDL) cholesterol in the blood. Other medications, such as fibrates, bile acid sequestrants, and niacin, may also be used to treat dyslipidemia. Several companies are involved in the dyslipidemia market, including Pfizer, Merck, AstraZeneca, Sanofi, and Novartis. These companies produce a variety of medications used to treat dyslipidemia, including statins, fibrates, and bile acid sequestrants. Additionally, there are several companies that specialize in developing and marketing dietary supplements for dyslipidemia, such as Omega-3 fatty acids and plant sterols. Show Less Read more